396 related articles for article (PubMed ID: 25634992)
21. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
Le Terrier C; Nordmann P; Buchs C; Poirel L
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
[TBL] [Abstract][Full Text] [Related]
22. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
Wang Q; Jin L; Sun S; Yin Y; Wang R; Chen F; Wang X; Zhang Y; Hou J; Zhang Y; Zhang Z; Luo L; Guo Z; Li Z; Lin X; Bi L; Wang H
Microbiol Spectr; 2022 Jun; 10(3):e0267021. PubMed ID: 35481835
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
Biedenbach DJ; Kazmierczak K; Bouchillon SK; Sahm DF; Bradford PA
Antimicrob Agents Chemother; 2015 Jul; 59(7):4239-48. PubMed ID: 25963984
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
Sader HS; Mendes RE; Pfaller MA; Shortridge D; Flamm RK; Castanheira M
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061754
[TBL] [Abstract][Full Text] [Related]
25. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
26. Novel mechanisms of resistance to β-lactam antibiotics in Haemophilus parainfluenzae: β-lactamase-negative ampicillin resistance and inhibitor-resistant TEM β-lactamases.
García-Cobos S; Arroyo M; Campos J; Pérez-Vázquez M; Aracil B; Cercenado E; Orden B; Lara N; Oteo J
J Antimicrob Chemother; 2013 May; 68(5):1054-9. PubMed ID: 23335113
[TBL] [Abstract][Full Text] [Related]
27. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
28. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE
J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387
[TBL] [Abstract][Full Text] [Related]
29. Occurrence of Aztreonam-Avibactam-Resistant NDM-5-Producing Escherichia coli in the Food Chain.
Sadek M; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0088221. PubMed ID: 34125588
[No Abstract] [Full Text] [Related]
30. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
[TBL] [Abstract][Full Text] [Related]
31. Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Livermore DM; Warner M; Mushtaq S; Woodford N
Antimicrob Agents Chemother; 2016 Jan; 60(1):554-60. PubMed ID: 26552987
[TBL] [Abstract][Full Text] [Related]
32. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
34. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
[TBL] [Abstract][Full Text] [Related]
35. Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
Chew KL; Tay MKL; Cheng B; Lin RTP; Octavia S; Teo JWP
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760136
[No Abstract] [Full Text] [Related]
36. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
Winkler ML; Papp-Wallace KM; Bonomo RA
J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
[TBL] [Abstract][Full Text] [Related]
37. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
Ourghanlian C; Soroka D; Arthur M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
[TBL] [Abstract][Full Text] [Related]
38. Global distribution of bla
Long H; Zhao F; Feng Y; Zong Z
Int J Antimicrob Agents; 2024 May; 63(5):107141. PubMed ID: 38484805
[No Abstract] [Full Text] [Related]
39. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
[TBL] [Abstract][Full Text] [Related]
40. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
